Recognition of Non-Operating Income and Expenses
Oncolys BioPharma Inc. (the filing company)
Foreign exchange gains from the revaluation of foreign-currency-denominated assets, interest income, share issuance costs including registration and license taxes related to the exercise of stock acquisition rights, and interest expenses
¥12 million in non-operating income and ¥5 million in non-operating expenses (amounts rounded down to the nearest million yen)
Cumulative first-quarter period of the fiscal year ending December 2026 (1 January 2026 to 31 March 2026)
As stated in the "Consolidated Financial Results for the First Quarter of the Fiscal Year Ending December 2026 [Japanese GAAP] (Non-consolidated)" released on 8 May 2026. This document does not provide specific details of any revisions.
| Item | Details |
|---|---|
| Event name | Recognition of Non-Operating Income and Expenses |
| Date of occurrence | 1 January 2026–31 March 2026 (cumulative first-quarter period) |
| Subject Entity | Oncolys BioPharma Inc. (the filing company) |
| Cause | Foreign exchange gains from the revaluation of foreign-currency-denominated assets, interest income, share issuance costs including registration and license taxes related to the exercise of stock acquisition rights, and interest expenses |
| Amount of Impact on Business Performance | ¥12 million in non-operating income and ¥5 million in non-operating expenses (amounts rounded down to the nearest million yen) |
| Accounting period in which recognized | Cumulative first-quarter period of the fiscal year ending December 2026 (1 January 2026 to 31 March 2026) |
| Impact on Earnings Forecast | As stated in the "Consolidated Financial Results for the First Quarter of the Fiscal Year Ending December 2026 [Japanese GAAP] (Non-consolidated)" released on 8 May 2026. This document does not provide specific details of any revisions. |
Items this document does not state (18)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The non-operating income consisted mainly of a ¥9 million foreign exchange gain resulting from the revaluation of foreign-currency-denominated assets and ¥3 million in interest income. The non-operating expenses consisted of ¥2 million in share issuance costs, including registration and license taxes related to the exercise of stock acquisition rights, and ¥2 million in interest expenses.